Sentences with phrase «immune checkpoint inhibitor drugs»

Following the 2011 FDA approval of ipilimumab (Yervoy ®), an immune checkpoint inhibitor drug, the first milestone toward this goal was achieved.

Not exact matches

BMS's drug, ipilimumab (Yervoy), was the first checkpoint inhibitor (a kind of cancer immunotherapy drug that essentially helps the immune system release its brake and go after tumor cells it might normally miss) to get approved in the US in 2011 for melanoma.

One class of immunotherapeutic drugs is known as «checkpoint» inhibitors, as they target checkpoints in immune system regulation to allow the body's natural defenses, such as white blood cells, to more effectively target the cancer.

In my experience, this marks both the first clinical trial of an approved drug with an effect on survival in advanced melanoma in the adjuvant setting, and, in this same setting, the first to study an immune checkpoint inhibitor in the adjuvant setting.

One recent tally found more than 1100 studies combining a popular new class called checkpoint inhibitor drugs, which unleash suppressed immune cells, with other treatments.

The cancer cells» defense strategy can be overcome by immune checkpoint inhibitor agents, including anti-PD-1 / PD - L1 antibodies, several kinds of which have received fast - track approval from the U.S. Food and Drug Administration (FDA).

Once again, researchers at Penn's Abramson Cancer Center have extended the reach of the immune system in the fight against metastatic melanoma, this time by combining the checkpoint inhibitor tremelimumab with an anti-CD40 monoclonal antibody drug.

A new class of drugs called immune checkpoint inhibitors block molecules on T cells that shut down immune response, freeing the immune system to attack tumors.

Results of an initial study of tumors from patients with lung cancer or head and neck cancer suggest that the widespread acquired resistance to immunotherapy drugs known as checkpoint inhibitors may be due to the elimination of certain genetic mutations needed to enable the immune system to recognize and attack malignant cells.

The novel drug combination allows the rapidly emerging cancer therapies called immune checkpoint inhibitors to be incorporated into a transplant patient's cancer treatment regimen.

Checkpoint inhibitors are a class of drugs designed to free the body's immune system to fight back against cancer.

The drugs, ipilimumab (Yervoy ®) and nivolumab (Opdivo ®), made by Bristol - Myers Squibb (BMS), are two immune checkpoint inhibitors that «release the brakes» on the immune system, allowing it to mount a stronger and more effective attack against cancer.

Through strategic partnerships with industry and nonprofit organizations, we gain access to a portfolio of priority drugs for testing within our expert focus groups, including checkpoint inhibitors, therapeutic vaccines, innate immune stimulants, targeted therapies, and many other promising treatments and technologies with high therapeutic potential.

In recent years, though, discoveries have led to a new class of drugs called checkpoint inhibitors, which have mobilized the immune system to see and go after cancer.

The study highlights an opportunity to combine this form of therapy with cancer immunotherapy drugs such as checkpoint inhibitors, which unleash the immune system's full cancer - fighting power, the researchers say.

The first three drugs are checkpoint inhibitors that «take the brakes off» the immune system and enable it to fight cancer; the last is an oncolytic virus therapy that stimulates stronger anti-tumor immune responses.

Checkpoint inhibitors are drugs used to «release the brakes» on the immune system, allowing the body to respond more aggressively to cancer.